The Pharmacy Times® Immuno-oncology Resource Center is a comprehensive resource for clinical news and expert insights on treatments that harness the body's immune system to fight cancer.
July 2nd 2025
The treatment becomes the first approved BCMAxCD3 bispecific antibody with the potential to achieve biweekly or monthly dosing in patients with relapsed/refractory multiple myeloma.
NCCN 2025: Managing Immune Checkpoint Inhibitor-Related Toxicities in Cancer Care
March 31st 2025Effective management of immune checkpoint inhibitor-related toxicities requires early intervention, evolving guideline adherence, and multidisciplinary collaboration, with steroids remaining a key treatment.
Read More
NCCN 2025: Immune Checkpoint Inhibitors Expand Treatment Options for Early-Stage NSCLC
March 29th 2025PD-L1 immune checkpoint inhibitors are now standard for early-stage non-metastatic non-small cell lung cancer (NSCLC), with neoadjuvant, adjuvant, and perioperative strategies improving survival and outcomes.
Read More
Conference Co-Chair and American Association for Cancer Research (AACR) Past President Elaine R. Mardis, PhD, explains that the conference provides pharmacy professionals with insights into the application of large-scale cancer genomics studies to real-world therapeutic responses.
Read More
Optimizing Immunotherapy in Resectable NSCLC: Adjuvant, Neoadjuvant, and Perioperative Strategies
February 26th 2025The administration of immunotherapy in adjuvant, neoadjuvant, and perioperative settings offers distinct benefits and challenges in resectable cancers, with recent clinical trials highlighting its potential to improve long-term outcomes and the need for further research into biomarkers and combination strategies.
Read More
Lifileucel Approval Paves the Way for Personalized Minimally-Invasive T-Cell Therapies
February 25th 2025The FDA’s accelerated approval of lifileucel (Amtagvi; Iovance Biotherapeutics) marks a major milestone in immunotherapy for metastatic melanoma, building on decades of research in tumor-infiltrating lymphocyte therapy.
Read More
James P. Allison and the Discovery of CTLA-4: How Immune Checkpoint Blockade Revolutionized Oncology
February 25th 2025Immunotherapy pioneer James P. Allison, PhD, revolutionized cancer treatment by discovering immune checkpoint blockade, leading to significant advances in survival rates and ongoing efforts to optimize immuno-oncology strategies.
Read More
Key Sessions and Opportunities for Pharmacists at the AACR Immunotherapy Conference
February 21st 2025The AACR Immunotherapy Conference 2025 will provide pharmacists with the opportunity to engage with cutting-edge cancer immunotherapy research, explore advancements in treatments, such as immune checkpoint inhibitors and CAR T-cell therapy, and connect with key leaders in the field.
Read More
Ketogenic Diet and β-Hydroxybutyrate May Enhance CAR T-Cell Therapy Efficacy
December 7th 2024A ketogenic diet and its key metabolite, β-hydroxybutyrate, enhance the efficacy of CAR T-cell therapy by improving metabolic fitness, cytokine production, and cellular expansion, offering a promising, safe strategy for optimizing cancer immunotherapy.
Read More
Advanced cell therapies are now saving the lives of people whose blood cancer would previously have been incurable. While the UK was quick to recognize the potential of these innovative therapies, patient access to these therapies may change without continued investment in the UK's cell therapy infrastructure.
Read More
Clinical research presented at ESMO 2024 highlights the significant survival benefits of perioperative and neoadjuvant immunotherapy with nivolumab and nivolumab plus ipilimumab, while emphasizing the role of biomarkers such as ctDNA and KRAS mutations in guiding treatment decisions.
Read More
An ESMO 2024 presentation explores the growing role of the gut microbiome in immunotherapy response, emerging diagnostic tools such as PCR chips, and innovative therapies such as fecal microbiota transplantation and microbiome-preserving strategies to improve patient outcomes.
Read More